HHS awarded $97.5M to Quidel Corp for OTC COVID-19 tests, with limited competition

Contract Overview

Contract Amount: $97,492,573 ($97.5M)

Contractor: Quidel Corp

Awarding Agency: Department of Health and Human Services

Start Date: 2022-12-07

End Date: 2023-04-07

Contract Duration: 121 days

Daily Burn Rate: $805.7K/day

Competition Type: NOT COMPETED

Number of Offers Received: 1

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: THE PURPOSE OF THIS CONTRACT IS TO PROCURE OF OVER THE COUNTER (OTC) COVID-19 TESTS.

Place of Performance

Location: SAN DIEGO, SAN DIEGO County, CALIFORNIA, 92121

State: California Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $97.5 million to QUIDEL CORP for work described as: THE PURPOSE OF THIS CONTRACT IS TO PROCURE OF OVER THE COUNTER (OTC) COVID-19 TESTS. Key points: 1. The contract focuses on procuring over-the-counter COVID-19 tests, a critical public health need. 2. Awarded to a single vendor, Quidel Corp, raising questions about competitive pricing and market exploration. 3. The contract duration is 121 days, suggesting a short-term or urgent need. 4. The fixed-price contract type aims to provide cost certainty for the government. 5. The value of the contract is substantial, reflecting the demand for diagnostic tools. 6. The specific product category is In-Vitro Diagnostic Substance Manufacturing.

Value Assessment

Rating: fair

Benchmarking the value of this contract is challenging without more detailed pricing information or comparisons to similar recent procurements for OTC COVID-19 tests. The awarded amount of $97.5 million for a 121-day period suggests a significant per-unit cost or volume. Given the urgency and nature of pandemic response, prices may reflect rapid deployment needs. However, the lack of competition limits the ability to assess if this represents the best possible value for taxpayer dollars.

Cost Per Unit: N/A

Competition Analysis

Competition Level: sole-source

This contract was awarded on a sole-source basis, meaning it was not competed among multiple vendors. This approach is typically used when only one vendor can provide the required goods or services, or in urgent situations where a competitive process would be impractical. The lack of competition means that the government did not benefit from the price discovery and innovation that typically arises from a bidding process.

Taxpayer Impact: Sole-source awards can lead to higher prices for taxpayers as there is no competitive pressure to drive down costs. It also limits opportunities for other qualified businesses to secure government contracts.

Public Impact

The primary beneficiaries are the public, who gain access to essential COVID-19 testing supplies. The services delivered include the procurement and distribution of over-the-counter COVID-19 tests. The geographic impact is likely national, aiming to meet demand across the United States. Workforce implications may include support for manufacturing, logistics, and distribution related to the tests.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Lack of competition may result in suboptimal pricing for taxpayers.
Sole-source awards can stifle innovation and limit market opportunities for other vendors.
Urgency-driven procurement might not allow for thorough market research on alternative solutions.
Dependence on a single supplier could pose supply chain risks if issues arise with the contractor.

Positive Signals

Ensures rapid availability of critical COVID-19 testing supplies during a public health need.
Direct award to a known entity can expedite delivery timelines.
Fixed-price contract provides budget certainty for the procured items.

Sector Analysis

The procurement of over-the-counter (OTC) COVID-19 tests falls within the broader healthcare and life sciences sector, specifically in the area of in-vitro diagnostics. This market is characterized by significant research and development, regulatory oversight (e.g., FDA), and a fluctuating demand driven by public health conditions. The size of the market for diagnostic tests can be substantial, especially during health crises. This contract represents a direct government purchase to meet immediate public health needs, rather than a long-term strategic investment in a specific technology.

Small Business Impact

This contract was not competed and does not appear to have a small business set-aside. The award to Quidel Corp, a large business, suggests that small businesses were not directly involved in fulfilling this specific contract. There is no information provided regarding subcontracting opportunities for small businesses within this award. This could represent a missed opportunity to engage the small business sector in critical public health supply chains.

Oversight & Accountability

Oversight for this contract would typically fall under the Department of Health and Human Services (HHS), specifically the Office of Assistant Secretary for Preparedness and Response (ASPR). Accountability measures would include monitoring contract performance against delivery schedules and quality standards. Transparency is limited due to the sole-source nature of the award. Inspector General jurisdiction would apply to any potential fraud, waste, or abuse related to the contract.

Related Government Programs

COVID-19 Testing Procurement
Public Health Emergency Response
Diagnostic Test Manufacturing
Over-the-Counter Medical Devices

Risk Flags

Sole-source award
Lack of competitive bidding
Potential for inflated pricing
Limited transparency

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $97.5 million to QUIDEL CORP. THE PURPOSE OF THIS CONTRACT IS TO PROCURE OF OVER THE COUNTER (OTC) COVID-19 TESTS.

Who is the contractor on this award?

The obligated recipient is QUIDEL CORP.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (Office of Assistant Secretary for Preparedness and Response).

What is the total obligated amount?

The obligated amount is $97.5 million.

What is the period of performance?

Start: 2022-12-07. End: 2023-04-07.

What is Quidel Corp's track record with government contracts, particularly for similar diagnostic products?

Quidel Corporation has a history of receiving government contracts, primarily related to diagnostic testing. While specific details for this contract are limited, their experience often involves supplying various types of diagnostic kits, including those for infectious diseases. Analyzing their past performance on similar awards, including delivery timeliness, product quality, and any past disputes or issues, would provide further insight into their reliability for this $97.5 million award. Government contract databases and past performance reviews would be the primary sources for this information, helping to assess their capability to meet the demands of this significant procurement.

How does the pricing of these OTC COVID-19 tests compare to market rates or other government procurements?

Direct comparison of pricing is difficult without access to the specific unit costs within this $97.5 million contract and comparable market data. However, the sole-source nature of this award raises concerns about whether the government secured the most competitive pricing. Typically, competitive bidding processes drive down unit costs. If similar tests were procured competitively around the same time, a comparison could reveal significant price differences. Factors such as volume discounts, urgency, and specific test performance characteristics would also influence pricing. A thorough value-for-money assessment would require benchmarking against both commercial prices and other government contracts for similar diagnostic supplies.

What are the specific risks associated with a sole-source award for essential medical supplies?

Sole-source awards for essential medical supplies carry several risks. Firstly, the lack of competition can lead to inflated prices, meaning taxpayers may overpay for the goods. Secondly, it limits the government's ability to explore alternative suppliers or innovative solutions that might be offered by other companies. Thirdly, reliance on a single vendor creates a potential bottleneck in the supply chain; if the sole provider experiences production issues, quality control problems, or delivery delays, the availability of critical supplies can be severely impacted. This dependence can be particularly risky during public health emergencies when demand is high and unpredictable.

What is the expected impact of this contract on the availability of OTC COVID-19 tests for the general public?

This contract is intended to directly increase the availability of over-the-counter (OTC) COVID-19 tests for the general public. By awarding $97.5 million to Quidel Corp for these tests, the Department of Health and Human Services (HHS) aims to ensure a sufficient supply to meet public demand, likely for distribution through various channels. The short duration of the contract (121 days) suggests it's addressing an immediate need or a specific surge in demand. The success of this contract in improving public access will depend on efficient distribution and the actual performance of the procured tests.

How does this contract fit into the broader federal strategy for managing the COVID-19 pandemic?

This contract represents a component of the federal government's ongoing strategy to manage the COVID-19 pandemic by ensuring access to diagnostic tools. Procuring OTC tests is crucial for enabling individuals to monitor their health status and make informed decisions, thereby helping to control the spread of the virus. Such procurements are typically part of a larger public health response that may also include vaccination campaigns, therapeutic treatments, and surveillance efforts. The scale of this award ($97.5 million) indicates a significant commitment to maintaining testing capacity, likely in response to current epidemiological trends or anticipated future needs.

What are the performance metrics and oversight mechanisms in place for this contract?

While specific performance metrics are not detailed in the provided data, standard oversight for such contracts would involve monitoring delivery schedules, ensuring the quality and efficacy of the tests meet regulatory standards (e.g., FDA EUA or approval), and verifying that the quantity procured matches the contract amount. The Department of Health and Human Services (HHS), through the Office of Assistant Secretary for Preparedness and Response (ASPR), would be responsible for contract administration and oversight. The fixed-price nature of the contract provides a degree of financial oversight by setting a ceiling on costs. Any deviations from the contract terms or performance failures would trigger corrective actions or potential penalties.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › In-Vitro Diagnostic Substance Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: NOT COMPETED

Solicitation Procedures: ONLY ONE SOURCE

Offers Received: 1

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 9975 SUMMERS RIDGE RD, SAN DIEGO, CA, 92121

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Manufacturer of Goods, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $97,492,573

Exercised Options: $97,492,573

Current Obligation: $97,492,573

Actual Outlays: $97,492,573

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Cost or Pricing Data: NO

Timeline